Updates are available Correction dated 2024-06-05
Click to view Correction: https://doi.org/10.1038/s41467-024-48995-7
-
Authors
Everson, Richard G. https://orcid.org/0000-0003-2809-3061
Hugo, Willy https://orcid.org/0000-0002-1426-7190
Sun, Lu
Antonios, Joseph https://orcid.org/0000-0002-5147-1377
Lee, Alexander https://orcid.org/0000-0002-4583-0740
Ding, Lizhong
Bu, Melissa https://orcid.org/0000-0002-5443-6542
Khattab, Sara https://orcid.org/0000-0002-4724-258X
Chavez, Carolina
Billingslea-Yoon, Emma
Salazar, Andres
Ellingson, Benjamin M.
Cloughesy, Timothy F. https://orcid.org/0000-0002-8656-7483
Liau, Linda M. https://orcid.org/0000-0002-4053-0052
Prins, Robert M. https://orcid.org/0000-0002-6282-6583
- License Information
-
More Information
Article History
Received: 12 January 2024
Accepted: 19 April 2024
First Online: 8 May 2024
Change Date: 5 June 2024
Change Type: Correction
Change Details: A Correction to this paper has been published:
Change Details: https://doi.org/10.1038/s41467-024-48995-7
Competing interests
: Andres Salazar is the Founder, CEO and Scientific Director for Oncovir, which provided the TLR agonist (Poly-ICLC) used in the trial. Linda M. Liau is a member of the Scientific Advisory Board for Northwest Bioetherapeutics, Inc, which has licensed the DC vaccine technology. All others declare no competing interests.
